Data from the ORAL Surveillance study (NCT02092467) suggested that malignancy risk is higher in people with active RA aged ≥50 years when using the JAK 1 inhibitor filgotinib vs TNF inhibitors. In this touchIMMUNOLOGY interview we spoke with Prof. Xavier Mariette (Paris-Saclay University, Ile-de-France, France) around his study investigating the malignancy incidence and event rates in clinical trials of filgotinib for the treatment of rheumatoid arthritis and ulcerative colitis.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Malignancy Events in the Filgotinib Rheumatoid Arthritis and Ulcerative Colitis Clinical Development Programs.’ (Abstract number: 0277) was presented at the ACR Convergence, November 10–14, 2022.
Questions
- What is known about the malignancy risk of janus kinase (JAK) 1 inhibitors in the treatment of rheumatoid arthritis (RA) and ulcerative colitis (UC)? (0:11)
- What were the aims and design of your study? (0:48)
- What was the incidence of malignancy events and what risk factors were identified? (2:19)
- What was the impact of filgotinib on malignancies in UC and RA? (3:34)
- What are the key take home messages of this study? (4:33)
Disclosures: Xavier Mariette discloses receiving honoraria from Astra-Zeneca, BMS, Galapagos, GSK, Novartis, and Pfizer.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ACR Convergence 2022.
